Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 886.00K | $ 2.33M | $ 18.74M | $ 0.00 |
| Gross Profit | $ 0.00 | $ -78.00K | $ 365.00K | $ 16.74M | $ -1.62M |
| Operating Income | $ -208.57M | $ -242.30M | $ -84.78M | $ -65.65M | $ -81.48M |
| EBITDA | $ -208.57M | $ -127.82M | $ -83.21M | $ -63.66M | $ -79.27M |
| Net Income | $ -208.02M | $ -338.79M | $ -83.81M | $ -65.80M | $ -80.89M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 603.09M | $ 339.28M | $ 55.71M | $ 93.13M | $ 146.27M |
| Total Assets | $ 608.48M | $ 341.86M | $ 71.14M | $ 109.93M | $ 161.62M |
| Total Debt | $ 0.00 | $ 84.56M | $ 4.63M | $ 5.06M | $ 5.45M |
| Net Debt | $ -89.42M | $ -188.89M | $ -30.23M | $ -10.08M | $ -84.65M |
| Total Liabilities | $ 90.68M | $ 157.84M | $ 20.84M | $ 25.98M | $ 21.79M |
| Stockholders' Equity | $ 517.80M | $ 184.02M | $ 50.30M | $ 83.94M | $ 139.83M |
| Cash Flow | |||||
| Free Cash Flow | $ -157.41M | $ -99.91M | $ -80.18M | $ -54.29M | $ -80.06M |
| Operating Cash Flow | $ -157.41M | $ -99.91M | $ -80.14M | $ -53.72M | $ -75.78M |
| Investing Cash Flow | $ -353.29M | $ -108.39M | $ 57.01M | $ -22.62M | $ -7.60M |
| Financing Cash Flow | $ 410.91M | $ 361.08M | $ 42.68M | $ 1.39M | $ 154.51M |